A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Fedratinib (Primary)
- Indications Myeloproliferative disorders
- Focus Adverse reactions; Therapeutic Use
- 26 Aug 2024 Planned End Date changed from 1 Nov 2025 to 1 Aug 2025.
- 26 Aug 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Aug 2025.
- 23 Nov 2021 New trial record